(0.34%) 5 117.35 points
(0.34%) 38 368 points
(0.39%) 15 990 points
(-0.97%) $83.04
(5.36%) $2.03
(0.35%) $2 355.40
(0.50%) $27.67
(4.12%) $960.05
(-0.26%) $0.932
(-0.47%) $10.97
(-0.57%) $0.796
(1.66%) $93.40
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 7.09%
@ $9.40
発行日: 15 2月 2024 @ 03:07
リターン: -28.72%
前回のシグナル: 2月 15 - 01:58
前回のシグナル:
リターン: 1.68 %
Live Chart Being Loaded With Signals
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications...
Stats | |
---|---|
本日の出来高 | 285 405 |
平均出来高 | 1.22M |
時価総額 | 878.90M |
EPS | $0 ( 2024-02-22 ) |
次の収益日 | ( $-0.720 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.40 |
ATR14 | $0.0100 (0.15%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-27 | Catinazzo Thomas | Sell | 348 | Common Stock |
2024-03-27 | Bergstrom Donald A | Sell | 765 | Common Stock |
2024-03-27 | Rahmer Peter | Sell | 298 | Common Stock |
2024-03-27 | Adams Brian | Sell | 348 | Common Stock |
2024-01-29 | Rahmer Peter | Sell | 1 651 | Common Stock |
INSIDER POWER |
---|
87.71 |
Last 99 transactions |
Buy: 4 152 455 | Sell: 399 360 |
ボリューム 相関
Relay Therapeutics, Inc. 相関
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Relay Therapeutics, Inc. 相関 - 通貨/商品
Relay Therapeutics, Inc. 財務諸表
Annual | 2023 |
収益: | $25.55M |
総利益: | $20.28M (79.37 %) |
EPS: | $-2.79 |
FY | 2023 |
収益: | $25.55M |
総利益: | $20.28M (79.37 %) |
EPS: | $-2.79 |
FY | 2022 |
収益: | $1.38M |
総利益: | $-2.75M (-199.06 %) |
EPS: | $-2.27 |
FY | 2021 |
収益: | $3.03M |
総利益: | $3.03M (100.00 %) |
EPS: | $-3.93 |
Financial Reports:
No articles found.
Relay Therapeutics, Inc.
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。